The vaginal and gastrointestinal microbiomes in gynecologic cancers: A review of applications in etiology, symptoms and treatment
Dana M. Chase(Creighton University), Melissa M. Herbst‐Kralovetz(University of Arizona), Bradley J. Monk(Creighton University), Alison Goulder(University of Arizona), Frédéric Zenhausern
Cited by 144
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Estrogen–gut microbiome axis: Physiological and clinical implications
|Maturitas|2017|948
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
The microbiome and gynaecological cancer development, prevention and therapy
|Nature Reviews Urology|2020|463